血清LncRNA PVT1、LncRNA H19表达与前列腺癌患者术后复发转移的关系

The relationship between the expression of serum LncRNA PVT1 and H19 and postoperative recurrence and metastasis of prostate cancer

摘要:

目的 探讨血清长链非编码RNA（LncRNA）浆细胞瘤可变易位基因1（PVT1）、LncRNA H19表达与前列腺癌患者术后复发转移的关系。方法 选取2016年5月—2018年5月南京医科大学附属常州市第二人民医院收治的169例前列腺癌患者作为前列腺癌组，统计患者术后3年复发转移率。另选取同期该院健康体检者74例作为对照组。qRT-PCR检测血清LncRNA PVT1、LncRNA H19表达。多因素Cox回归分析前列腺癌患者术后复发转移影响因素。ROC曲线分析血清LncRNA PVT1、LncRNA H19表达对前列腺癌患者术后复发转移的预测价值。结果 前列腺癌组血清LncRNA PVT1、LncRNA H19相对表达量高于对照组（P <0.05）。复发转移组与未复发转移组TNM分期、Gleason评分、PSA、LncRNA PVT1、LncRNA H19表达比较，差异有统计学意义（P <0.05），两组年龄、病理类型、肿瘤直径、分化程度比较差异无统计学意义（P >0.05）。多因素Cox回归分析结果显示，TNM分期Ⅲ期［O^R=3.722（95 CI：1.416，7.784），P <0.05］、Gleason评分≥7分［O^R=4.626（95% CI：1.670，9.815），P <0.05］、LncRNA PVT1［O^R=1.982（95 CI%：1.521，2.584），P <0.05］、LncRNA H19［O^R=1.868（95% CI：1.327，2.630），P <0.05］是前列腺癌患者术后复发转移的独立危险因素。联合血清LncRNA PVT1、LncRNA H19表达预测AUC大于单独预测。结论 前列腺癌患者血清LncRNA PVT1、LncRNA H19高表达，为术后复发转移的独立危险因素，可作为前列腺癌患者术后复发转移预测指标。

Abstract:

Objective To investigate the relationship between the expression of serum long non-coding RNA (LncRNA) plasmacytoma variant translocation 1 (PVT1) and H19 and postoperative recurrence and metastasis of prostate cancer.Methods A total of 169 prostate cancer patients admitted to Changzhou Second People's Hospital from May 2016 to May 2018 were selected as the prostate cancer group, and the recurrence and metastasis rate at 3 years after surgery was analyzed. Another 74 healthy individuals undergoing the physical examination in the Changzhou Second People's Hospital during the same period were selected as the control group. The expression of serum PVT1 and H19 was detected by qRT-PCR. Multivariate Cox regression model was used to analyze the factors affecting the postoperative tumor recurrence and metastasis in prostate cancer patients. The receiver operating characteristic (ROC) curve was applied to determine the predictive value of serum PVT1 and H19 expression for postoperative recurrence and metastasis of prostate cancer.Results The serum levels of LncRNA PVT1 and H19 were higher in the prostate cancer group compared with the control group (P < 0.05). The TNM stage, the Gleason score, and the expression of serum prostate-specific antigen (PSA), PVT1 and H19 (P < 0.05) instead of the age, tumor diameter, and the degree of tumor differentiation (P > 0.05) were different between those with and without recurrence and metastasis. Multivariate Cox regression analysis showed that stage III cancer [O^R = 3.722 (95% CI: 1.416, 7.784), P = 0.008], Gleason score ≥ 7 [O^R = 4.626 (95% CI: 1.670, 9.815), P = 0.003], LncRNA PVT1 [O^R = 1.982 (95% CI: 1.521, 2.584), P<0.001], and LncRNA H19 [O^R = 1.868 (95% CI: 1.327, 2.630), P < 0.001] were independent risk factors for postoperative recurrence and metastasis of prostate cancer. The area under the ROC curve of the combined detection of PVT1 and H19 was greater than that of PVT1 or H19 alone for predicting postoperative tumor recurrence and metastasis in prostate cancer patients (P < 0.05).Conclusions The LncRNA PVT1 and H19 are highly expressed in prostate cancer patients, and are independent risk factors for postoperative recurrence and metastasis of prostate cancer. Thus, LncRNA PTV1 and H19 can be established as predicting indicators for postoperative tumor recurrence and metastasis in prostate cancer patients.